ARS-1323

Name: ARS-1323
Brand: MedChemExpress
SKU: HY-U00416
Rating: 5.0 (1 reviews)

Cat. No.: HY-U00416 Purity: 99.67%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

ARS-1323, the racemate of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.

For research use only. We do not sell to patients.

ARS-1323 Chemical Structure

CAS No. : 1698024-73-5

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 176	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 176	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 160	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 260	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of ARS-1323:

ARS-1630 In-stock
ARS-1620 In-stock
ARS-1323-alkyne Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

View All Isoforms

K-Ras H-Ras N-Ras Ras

Biological Activity
Purity & Documentation
References
Customer Review

Description

ARS-1323, the racemate of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.

IC₅₀ & Target

KRas G12C

Cellular Effect

Cell Line	Type	Value	Description	References
CT26	IC₅₀	> 20 μM Compound: ARS-1620	Antiproliferative activity against mouse CT26 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against mouse CT26 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 35276423]
HCT-116	IC₅₀	> 20 μM Compound: ARS-1620	Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 35276423]
HeLa	IC₅₀	> 20 μM Compound: ARS-1620	Antiproliferative activity against human HeLa cells harboring wild type KRAS assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells harboring wild type KRAS assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 35276423]
MIA PaCa-2	IC₅₀	1.06 μM Compound: 1; ARS1620	Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as growth inhibition measured after 72 hrs by CCK8 assay Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as growth inhibition measured after 72 hrs by CCK8 assay	[PMID: 33309163]
NCI-H23	IC₅₀	1.06 μM Compound: ARS-1620	Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35987104]
NCI-H358	IC₅₀	0.2 μM Compound: ARS-1620	Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 35276423]
NCI-H358	IC₅₀	1.59 μM Compound: ARS-1620	Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35987104]
PANC-1	IC₅₀	> 20 μM Compound: ARS-1620	Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 35276423]
SW1990	IC₅₀	> 20 μM Compound: ARS-1620	Antiproliferative activity against human SW1990 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human SW1990 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 35276423]

Molecular Weight

430.84

Formula

C₂₁H₁₇ClF₂N₄O₂

CAS No.

1698024-73-5

Appearance

Solid

Color

White to off-white

SMILES

O=C(C=C)N1CCN(C2=NC=NC3=C2C=C(Cl)C(C4=C(O)C=CC=C4F)=C3F)CC1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (232.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3210 mL	11.6052 mL	23.2105 mL
5 mM	0.4642 mL	2.3210 mL	4.6421 mL
10 mM	0.2321 mL	1.1605 mL	2.3210 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.67%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (252 KB) HNMR (143 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Liansheng Li, et al. Inhibitors of kras g12c. WO 2015054572 A1.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3210 mL	11.6052 mL	23.2105 mL	58.0262 mL
	5 mM	0.4642 mL	2.3210 mL	4.6421 mL	11.6052 mL
	10 mM	0.2321 mL	1.1605 mL	2.3210 mL	5.8026 mL
	15 mM	0.1547 mL	0.7737 mL	1.5474 mL	3.8684 mL
	20 mM	0.1161 mL	0.5803 mL	1.1605 mL	2.9013 mL
	25 mM	0.0928 mL	0.4642 mL	0.9284 mL	2.3210 mL
	30 mM	0.0774 mL	0.3868 mL	0.7737 mL	1.9342 mL
	40 mM	0.0580 mL	0.2901 mL	0.5803 mL	1.4507 mL
	50 mM	0.0464 mL	0.2321 mL	0.4642 mL	1.1605 mL
	60 mM	0.0387 mL	0.1934 mL	0.3868 mL	0.9671 mL
	80 mM	0.0290 mL	0.1451 mL	0.2901 mL	0.7253 mL
	100 mM	0.0232 mL	0.1161 mL	0.2321 mL	0.5803 mL

ARS-1323 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ARS-13231698024-73-5ARS1323ARS 1323RasInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

ARS-1323

Customer Review

Other Forms of ARS-1323:

ARS-1323 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

ARS-1323 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report